Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/22699
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBassukas, I. D.en
dc.contributor.authorGamvroulia, C.en
dc.contributor.authorZioga, A.en
dc.contributor.authorNomikos, K.en
dc.contributor.authorFotika, C.en
dc.date.accessioned2015-11-24T19:26:10Z-
dc.date.available2015-11-24T19:26:10Z-
dc.identifier.issn1365-4632-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22699-
dc.rightsDefault Licence-
dc.subjectAdjuvants, Immunologic/*administration & dosageen
dc.subjectAdministration, Cutaneousen
dc.subjectAgeden
dc.subjectAminoquinolines/*administration & dosageen
dc.subjectCombined Modality Therapyen
dc.subject*Cryosurgeryen
dc.subjectHumansen
dc.subjectHutchinson's Melanotic Freckle/*therapyen
dc.subjectMaleen
dc.subjectSkin Neoplasms/*therapyen
dc.titleCryosurgery during topical imiquimod: a successful combination modality for lentigo malignaen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1111/j.1365-4632.2008.03562.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18412875-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/store/10.1111/j.1365-4632.2008.03562.x/asset/j.1365-4632.2008.03562.x.pdf?v=1&t=h0oyore4&s=444775c337d4c4bcf39589144d89f782bfe7fc3b-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2008-
heal.abstractBACKGROUND: Either cryosurgery or topical imiquimod have been used to treat patients with lentigo maligna in cases where surgery is not feasible. METHODS: We report a patient with lentigo maligna, who was treated with the combination of topical imiquimod and cryosurgery, and review the rationale, which led us to design the present combined cryo-immunological treatment modality. RESULTS: Sustained clearance of lentigo maligna to date (26 months after treatment). The successful treatment of this patient was based on the following rationale: A cryosurgery session during continuing imiquimod application may: (i) reinforce apoptosis of tumor cells; (ii) strengthen antiangiogenesis in the treated tumor; and (iii) build-up a potent tumor-destructive immune response by a cascade of events starting with imiquimod-promoted attraction of immature dendritic antigen-presenting cells (DCs) into the tumor. DCs further mature within the tumor-antigen-rich environment of subsequently cryo-destructed tumor and upon imiquimod-driven migration into the peripheral lymph nodes can stimulate a specific antineoplastic cell-mediated immunity. Finally, continuing imiquimod application after cryosurgery may increase recruitment of activated effector cells into the tumor tissue leading to its destruction. CONCLUSION: Cryosurgery during continued topical imiquimod seems to be a promising treatment for lentigo maligna.en
heal.journalNameInt J Dermatolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Bassukas-2008-Cryosurgery during t.pdf95.26 kBAdobe PDFView/Open    Request a copy


This item is licensed under a Creative Commons License Creative Commons